PRDM14

Across TCGA pan-cancer cohorts, PRDM14 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PRDM14 data layer compared with 16 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher PRDM14 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRDM14 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

SARC, SCLC, and UCEC are the cancer types where PRDM14 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.065	0.632	<.001	6	view →
SCLC	OS	Median	All	0.164	0.661	<.001	6	view →
UCEC	DFS	Median	II,III,IV	0.915	0.439	.033	6	view →
PRAD	OS	Median	All	0.265	0.884	<.001	4	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SKCM	DFS	Median	III,IV	0.841	0.219	.026	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PRDM14–SARC (DFS)

Open the SARC breakdown →